Next Article in Journal
Spatiotemporal and Socioeconomic Risk Factors for Dengue at the Province Level in Vietnam, 2013–2015: Clustering Analysis and Regression Model
Next Article in Special Issue
Challenges in Tuberculosis Clinical Trials in the Face of the COVID-19 Pandemic: A Sponsor’s Perspective
Previous Article in Journal
The Predictive Factors for Severe Leptospirosis Cases in Kedah
Open AccessReview

Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis

1
Institute for Liver and Digestive Health, Division of Medicine, University College London, London NW3 2PF, UK
2
School of Respiratory Medicine, University College London, London NW3 2PF, UK
3
School of Medicine, La Sapienza University, Rome 00185, Italy
*
Author to whom correspondence should be addressed.
Trop. Med. Infect. Dis. 2020, 5(2), 80; https://doi.org/10.3390/tropicalmed5020080
Received: 26 April 2020 / Revised: 10 May 2020 / Accepted: 12 May 2020 / Published: 15 May 2020
(This article belongs to the Special Issue COVID-19: Current Challenges and Future Perspectives)
The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2–3%) and 1% (95% CI; 1–2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients. View Full-Text
Keywords: COVID-19; SARS-CoV-2; hepatitis B and C; cirrhosis; chronic kidney disease; alcohol-related liver disease; nonalcoholic steatohepatitis; necrosis COVID-19; SARS-CoV-2; hepatitis B and C; cirrhosis; chronic kidney disease; alcohol-related liver disease; nonalcoholic steatohepatitis; necrosis
Show Figures

Figure 1

MDPI and ACS Style

Oyelade, T.; Alqahtani, J.; Canciani, G. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Trop. Med. Infect. Dis. 2020, 5, 80.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop